Physicians' Academy for Cardiovascular Education

Lp(a)

Follow news, literature, education and expert opinions on the emerging role of Lp(a) as riks factor and therapeutic target in cardiovascular disease

No role of Lp(a) in thrombosis

3' education - June 16, 2022 - Prof. Alberico Catapano, PhD

How to overcome the excess ASCVD risk conferred by Lp(a)?

3' education - June 1, 2022 - Prof. Alberico Catapano, PhD

Beginning of an era: Treatment of elevated Lp(a)

3' education - Apr. 6, 2022 - Steven Nissen, MD

Working towards eradication of CV risk

10' education - Dec. 15, 2021 - Prof. Erik Stroes, MD, PhD

Lp(a) as therapeutic target - now and in the future

10' education - Oct. 28, 2021 - Prof. Erik Stroes, MD, PhD - Online CME

Understanding the increased CV risk of high Lp(a) levels

10' education - Sep. 28, 2021 - Prof. Florian Kronenberg, MD, PhD - Online CME

Why focus on Lp(a)?

10' education - Sep. 13, 2021 - Prof. Naveed Sattar, MD, PhD - Online CME

Introduction: Lp(a), a new lipid frontier in CV risk management & target for therapy

10' education - Nov. 3, 2020 - Prof. Erik Stroes, MD

Is there a role for PCSK9 inhibition in patients with high Lp(a)?

10' education - Nov. 2, 2020 - Prof. Vera Bittner, MD - Online CME

Novel strategies to lower Lp(a)

10' education - Oct. 27, 2020 - Prof. Sam Tsimikas, MD - Online CME

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD

Why worry about high Lp(a) and how to assess Lp(a) levels?

10' education - Oct. 7, 2020 - Pia Kamstrup, MD, PhD - Online CME

Familial Hypercholesterolemia and Lp(a)

10' education - July 14, 2020 - Nick Nurmohamed, MD

Treatment goals for LDL-c-lowering and emerging evidence for the importance of Lp(a)

10' education - May 26, 2020 - Prof. J. Wouter Jukema, MD - Leiden, The Netherlands

Assessing residual lipid risk with advanced testing

5' education - Feb. 17, 2020 - Samia Mora, MD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

Are we ready for prime-time Lp(a) assay standardization?

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Santica Marcovina

LDL vs Lp(a) cholesterol: confounding

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Calvin Yeang, MD, PhD

Associations of Lp(a) with CV morbidity and mortality

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Pia Kamstrup, MD, PhD

Phase II data on Lp(a) lowering, followed by NHLBI recommendation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Sam Tsimikas

Entry of Lp(a) into the CV arena

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Florian Kronenberg, MD

Lp(a) apheresis and CVD risk modulation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Elisa Waldmann, MD

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD

Lp(a) and calcification in aortic stenosis

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Kang He Zheng, MD

Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction

3' education - May 29, 2019 - Maastricht. The Netherlands - Prof. Chapman, DSc

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands - Online CME

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD

Lowering Lp(a) potently and safely with antisense technology

3' education - Nov. 20, 2018 - Sotirios Tsimikas, MD

No role of Lp(a) in thrombosis

3' education - June 16, 2022 - Prof. Alberico Catapano, PhD

EAS 2022 "According to [these] data, there is no reason why you should give aspirin to an individual with high Lp(a)," says prof. Catapano. He recapitulates the findings of a study by Olmastroni and colleagues.

How to overcome the excess ASCVD risk conferred by Lp(a)?

3' education - June 1, 2022 - Prof. Alberico Catapano, PhD
It is recommended that risk factors, such as LDL-c, should be controlled in patients with high Lp(a) levels. Prof. Catapano briefly summarizes the findings of a study on this topic that was presented at EAS 2022.

EAS 2022 It is recommended that risk factors, such as LDL-c, should be controlled in patients with high Lp(a) levels. Prof. Catapano briefly summarizes the findings of a study on this topic that was presented at EAS 2022.

How much LDL-c lowering is needed to overcome the increased ASCVD risk caused by high Lp(a)?

News - May 25, 2022

EAS 2022 Thus far there is no effective therapy to reduce Lp(a) levels. Risk factor modification is recommended for persons with high Lp(a), but how much LDL-c lowering is needed to overcome the increased ASCVD risk caused by high Lp(a)?

Lp(a) is not associated with thrombotic events

News - May 25, 2022

EAS 2022 A study found that Lp(a) is not associated with VTE and the increased risk of MI caused by high Lp(a) levels is unlikely to be decreased by antiplatelet or antithrombin therapy.

Lp(a) level increases during childhood

Literature - May 2, 2022 - De Boer LM, et al. - Atherosclerosis. 2022

Lp(a) levels are thought to stay stable over time, at least in adults. As several lipid values change during childhood, Lp(a) values were measured in a large cohort of children. The result: Lp(a) levels increased with age.

Combination of high Lp(a) and high BMI confers highest risk of calcific aortic valve disease

Literature - Apr. 20, 2022 - Kaltoft M et al. - J Am Coll Cardiol. 2022

The combination of high Lp(a) levels and high BMI conferred a 3.5-fold risk of CAVD compared with both risk factors in the bottom 50%. Absolute 10-year risk of CAVD was higher in men than in women and increased with higher age, Lp(a) and BMI.

Beginning of an era: Treatment of elevated Lp(a)

3' education - Apr. 6, 2022 - Steven Nissen, MD
A phase 1 study showed that a siRNA targeting LPA mRNA reduced Lp(a) up to 98%. “It is an early study, this has got a long way to go, but we are optimistic that we are beginning an era where we going to be able to treat this disorder”, Nissen said.

ACC 2022 A phase 1 study showed that a siRNA targeting LPA mRNA reduced Lp(a) up to 98%. “It is an early study, this has got a long way to go, but we are optimistic that we are beginning an era where we are going to be able to treat this disorder”, Nissen said.

siRNA targeting LPA mRNA lowers Lp(a) levels

News - Apr. 3, 2022

ACC 2022 A phase 1 single ascending dose study showed that subcutaneous injection of SLN360, an siRNA targeting mRNA for the LPA gene, lowered Lp(a) up to 98% in adults with elevated Lp(a) levels.

Elevated Lp(a) associated with adverse plaque progression in ASCVD

Literature - Jan. 26, 2022 - Kaiser Y et al. - J Am Coll Cardiol. 2022

A study shows that elevated Lp(a) is independently associated with accelerated progression of low-attenuation plaque in patients with advanced multivessel CAD on guideline-directed preventive therapies.

Working towards eradication of CV risk

10' education - Dec. 15, 2021 - Prof. Erik Stroes, MD, PhD
Achieving LDL-c target, measurements of risk factors, and a need for tailored therapy choices are three important factors to reduce (residual) CV risk. Prof. Stroes briefly discusses these three topics.

Achieving LDL-c target, measurements of risk factors, and a need for tailored therapy choices are three important factors to reduce (residual) CV risk. Prof. Stroes briefly discusses these three topics.

Impact of routine measurement of Lp(a) on CV risk reclassification

Literature - Dec. 6, 2021 - Nurmohamed NS, et al. - Eur J Prev Cardiol 2021
A case-control study in the Netherlands found an almost 3-fold increased CVD risk in those with very high Lp(a) levels. Addition of Lp(a) to risk scores for patients with very high Lp(a) levels resulted in a higher percentage of patients being reclassified.

A case-control study in the Netherlands found an almost 3-fold increased CVD risk in those with very high Lp(a) levels. Addition of Lp(a) to risk scores for patients with very high Lp(a) levels resulted in a higher percentage of patients being reclassified.

E-learning Lp(a): from CV risk marker to therapeutic target

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

In this e-learning program, three experts explain why it is important to measure Lp(a) levels. Furthermore, they describe the effects of currently available lipid-lowering treatments on Lp(a) levels and talk about potential therapies for Lp(a) lowering which are currently under investigation.